

1 **U-shaped effect of blood pressure on structural OCT metrics and retinal blood flow**
2 **autoregulation in ophthalmologically healthy subjects**

3
4 Konstantinos Pappelis,^{1,2} Nomdo M. Jansonius^{1,2}

- 5
6 1. Department of Ophthalmology, University of Groningen, University Medical Center
7 Groningen, Groningen, The Netherlands
8 2. Graduate School of Medical Sciences (Research School of Behavioural and Cognitive
9 Neurosciences), University of Groningen, Groningen, The Netherlands

10
11 Correspondence: K. Pappelis, Dept. of Ophthalmology, University Medical Center Groningen,
12 P.O.Box 30.001, 9700 RB Groningen, Netherlands. Phone: +31 50 3612510; Fax: +31 50
13 3611709; e-mail: k.pappelis@rug.nl

14
15 E-mail co-authors: n.m.jansonius@umcg.nl

16
17 Running head: Blood pressure and structural OCT: a U-shaped association

18
19 Conflict of interest: No conflicting relationships exist for any author.

20
21 Financial support: European Union's Horizon 2020 Innovative Training Networks Program,
22 under the Marie Skłodowska – Curie grant, Project ID 675033. The funding organization had no
23 role in the design, conduct, analysis, or publication of this research.

24
25 Word count: 4165 (main text); 350 (Abstract)

26
27 Meeting presentation: European Association for Vision and Eye Research (EVER); Nice, 3rd-6th
28 October 2018.

29
30 Keywords: glaucoma, optical coherence tomography, blood pressure, blood flow, autoregulation

31
32 Abbreviations/Acronyms: AHT, arterial hypertension; AR, autoregulatory reserve; BMI, body
33 mass index; BP, blood pressure; CRAE, central retinal artery equivalent; CRVE, central retinal
34 vein equivalent; DBP, diastolic blood pressure; FD, fractal dimension; GCIPL, ganglion cell-

35 inner plexiform layer; IOP, intraocular pressure; IQR, interquartile range; LARL, lower
36 autoregulation limit; MAP, mean arterial pressure; mRNFL, macular retinal nerve fiber layer;
37 NTG, normal-tension glaucoma; OCT, optical coherence tomography; OCT-A, optical
38 coherence tomography-angiography; ONH, optic nerve head; OPP, ocular perfusion pressure;
39 pRNFL, peripapillary retinal nerve fiber layer; RBF, retinal blood flow; RGC, retinal ganglion cell;
40 RNFL, retinal nerve fiber layer; RPP, retinal perfusion pressure; RVR, retinal vascular
41 resistance; SBP, systolic blood pressure; SD, standard deviation; SEQ, spherical equivalent.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

69 **Abstract**

70

71 **Objective:** 1) To investigate the effect of low blood pressure (BP), treated arterial hypertension
72 (AHT), and untreated AHT on the ganglion cell-inner plexiform layer (GCIPL) and the retinal
73 nerve fiber layer (RNFL) thickness of non-glaucomatous eyes and 2) to elucidate whether this
74 effect is related to crossing the lower limit of retinal blood flow (RBF) autoregulation.

75

76 **Design:** Cross-sectional, case-control.

77

78 **Subjects:** We included 96 eyes of 96 ophthalmologically healthy subjects (age 50-65).
79 Participants were prospectively recruited from a large-scale cohort study in the northern
80 Netherlands (n=167,000; Lifelines Biobank). They were allocated to four groups (low BP, normal
81 BP [controls], treated AHT, untreated AHT), based on information from previous visits and strict
82 distribution criteria.

83

84 **Methods:** Inner retinal layer thicknesses were obtained with optical coherence tomography
85 (OCT). Fractal dimension of the superficial microvasculature was quantified with OCT-
86 angiography and customized software. Central retinal vessel diameters were obtained from
87 fundus images. BP and intraocular pressure measurements were also acquired. Measurements
88 were combined with a validated physiological model to estimate vascular outcome measures.
89 Structural and vascular metrics were compared across groups and mediation analysis was
90 performed.

91

92 **Main outcome measures:** Structural: macular GCIPL and RNFL (mRNFL), peripapillary RNFL
93 (pRNFL) thickness. Vascular: RBF, retinal vascular resistance (RVR), autoregulatory reserve
94 (AR).

95

96 **Results:** Compared to controls, GCIPL was thinner in the low BP group ($P=0.013$), treated
97 hypertensives ($P=0.007$), and untreated hypertensives ($P=0.007$). Treated hypertensives
98 exhibited the thinnest mRNFL ($P=0.001$), temporal pRNFL ($P=0.045$), and inferior pRNFL
99 ($P=0.034$). In multivariable analysis, RBF was mediating the association of GCIPL thickness
100 with BP within the combined low BP group and controls ($P=0.003$), RVR together with AR were
101 mediating the same association within the combined treated hypertensives and controls
102 ($P=0.001$ and $P=0.032$), and RVR was mediating the association within the combined untreated
103 antihypertensives and controls ($P=0.022$).

104

105 **Conclusions:** We uncovered GCIPL and RNFL thinning related to both tails of the BP
106 distribution. GCIPL thinning was associated with reduced RBF autoregulatory capacity. This
107 predisposition to glaucomatous damage could explain the frequent epidemiological finding of
108 increased glaucoma risk in certain subgroups, such as subjects with nocturnal BP dipping or
109 aggressively treated AHT. Longitudinal studies could confirm this postulation.

110

111

112

113

114

115

116

117

118

119

120

121 Introduction

122

123 Glaucoma is a chronic optic neuropathy characterized by thinning of the retinal nerve
124 fiber layer (RNFL), loss of retinal ganglion cells (RGCs), and progressive visual function
125 decline.¹ While elevated intraocular pressure (IOP) is considered as the most important
126 modifiable risk factor, glaucoma may also manifest in those with apparently normal IOP (normal-
127 tension glaucoma [NTG]).²⁻⁴ Therefore, certain components of the disease remain elusive or
128 insufficiently addressed.

129 It has been proposed that low or unstable blood supply could lead to reduced
130 oxygenation of the RGCs.^{4,5} Current assessment of RGC structure is based on Optical
131 Coherence Tomography (OCT), while its extensions, OCT-angiography (OCT-A) and Doppler
132 OCT, enable the non-invasive evaluation of retinal perfusion.⁶⁻⁸ These methods have already
133 revealed that reduced blood flow predicts visual field (VF) deterioration, independently of neural
134 tissue damage.⁹⁻¹¹ However, after the onset of the disease, it is impossible to disentangle if
135 perfusion deficits are the cause (low supply) or consequence (low demand) of glaucomatous
136 optic neuropathy (GON). This realization is known as the ‘chicken-egg’ dilemma in glaucoma.

137 From a hemodynamic perspective, blood flow is determined by the balance between
138 ocular perfusion pressure (OPP) and vascular resistance.¹² Therefore, low blood pressure (BP)
139 could result in low OPP, thus increasing the risk for glaucoma incidence and progression,
140 possibly due to flow-mediated damage to the RGCs. Indeed, this has been observed in some
141 cross-sectional and longitudinal population-based studies.¹³⁻¹⁶ However, other studies do not
142 confirm this finding, while there is also evidence that this association becomes relevant only
143 when low BP manifests as pronounced nocturnal dipping.^{17,18} On the other hand, while arterial
144 hypertension (AHT) is also frequently reported as a risk factor for glaucoma, conflicting results
145 exist on whether BP reduction exacerbates or protects from GON, possibly depending on
146 individual medication effects and on how aggressive the treatment strategy is.¹⁹⁻²⁶

147 This study focuses on ophthalmologically healthy subjects, rather than glaucoma
148 subjects. This is essential, because the next logical step in approaching the ‘chicken-egg’
149 dilemma is to move back in the disease time course and study the effect of BP on retinal blood
150 flow (RBF) and the RGCs, prior to any glaucoma onset. To investigate RBF, we look into the
151 retinal microcirculation, which demonstrates the ability of autoregulation, i.e., active modification
152 of vascular caliber in response to local signals.²⁷ This property protects the tissue from
153 ischemia, in case of OPP drops. Recently, we proposed and validated a microcirculation model
154 predicting which healthy subjects are more prone to hypoperfusion, by estimating their lower
155 autoregulation limit (LARL) through OCT-A, fundus imaging, and other clinical examinations.²⁸

156 In the present study, we hypothesized an inverse U-shaped association between BP
157 status and structural OCT measures in non-glaucomatous eyes. While the detrimental effect of
158 AHT to the RGCs and their axons has been previously documented, this effect has not been
159 studied in subjects with low BP, nor has it been examined in combination with RBF
160 autoregulation.^{29–32} Studies until now have used linear models to describe the association
161 between BP and structural OCT measures, thus potentially neglecting any signal coming from
162 the left tail of the distribution.^{33,34}

163 Therefore, the aims of this study were 1) to investigate the effect of low BP, treated AHT,
164 and untreated AHT on the inner retinal layer thicknesses of non-glaucomatous eyes and 2) to
165 elucidate whether this effect is related to crossing the lower limit of RBF autoregulation. For this
166 purpose, we performed multimodal structural and vascular imaging in ophthalmically healthy
167 normotensive controls, treated arterial hypertensives, and individuals belonging to the lower and
168 higher (untreated) tails of the BP distribution. Participants were selected from the large-scale
169 population-based Lifelines cohort, which enabled us to study the real extremes, especially from
170 the low BP tail, in an unbiased manner.

171

172

173 **Methods**

174

175 *Study design and population*

176

177 For this cross-sectional, case-control study, we prospectively recruited subjects via
178 targeted invitation among the participants of a large-scale prospective cohort study of the
179 northern Netherlands (Lifelines Biobank; n=167,000).³⁵ Subjects were invited based solely on
180 their BP status and age. Following a strict selection procedure, 105 participants between 50 and
181 65 years of age satisfied both the BP criteria (see next paragraph) and the ophthalmic and
182 medical history inclusion criteria: unoperated eyes; best-corrected visual acuity ≥ 0.8 ; spherical
183 refractive error between -3 and +3 D; cylinder not exceeding 2 D; IOP ≤ 21 mmHg (non-contact
184 tonometer Tonoref II, Nidek, Aichi, Japan); no reproducibly abnormal VF test locations
185 (Frequency Doubling Technology [C20-1 screening mode], Carl Zeiss, Jena, Germany); no
186 family history of glaucoma; no ophthalmic, hematologic, or cardiovascular disease (except for
187 AHT), and no diabetes. We performed additional documentation of ophthalmic health with the
188 subsequent imaging sessions (see *Data collection*). We allocated participants to four non-
189 overlapping groups: 1) low BP, 2) normal BP (controls), 3) treated AHT, and 4) untreated AHT.
190 Group definitions (see next paragraph) were based on previous epidemiological evidence on the
191 association between BP status and glaucoma.^{15,16} All participants provided written informed
192 consent. The ethics board of the University Medical Center Groningen approved the study
193 protocol (#NL61508.042.17). The study followed the tenets of the Declaration of Helsinki.

194

195 *Blood pressure group definitions*

196

197 We defined low BP (group 1) as both systolic and diastolic BP (SBP, DBP) lower than
198 the 10th percentiles of the age-matched population (110 mmHg and 65 mmHg, respectively),

199 without any AHT record. This criterion had to be confirmed on at least two previous, separate
200 occasions (ascertaining that subjects truly belonged to the tail of the distribution and did not
201 regress towards the mean). We defined untreated AHT (group 4) similarly, the criteria being
202 both SBP and DBP higher than the 90th percentiles of the age-matched population (149 mmHg
203 and 88 mmHg, respectively), verified at least twice previously. Subjects of this group were
204 aware of their BP status, but never made use of antihypertensive medication, by choice. For
205 treated AHT (group 3), we randomly invited participants documented as receiving (and still
206 making uninterrupted use of) antihypertensive medication for at least one year. Lastly, we
207 defined normal BP (group 2) as both SBP and DBP within 1 standard deviation (SD) from the
208 mean of the age-matched population (SBP: 113 mmHg to 143 mmHg and DBP: 67 mmHg to 85
209 mmHg, measured on site) and no previous record of AHT.

210

211 *Data collection*

212

213 All participants were examined at the same time of the day (5:00 PM-6:30 PM) and were
214 not given any instructions regarding their routine prior to their visit. Following screening (see
215 previous section), we applied mydriatic drops that have been shown to not affect RBF
216 (tropicamide 0.5%).³⁶ After the participants had rested in a quiet room for 20 minutes, we
217 recorded BP from the brachial artery, in sitting position, with an automatic monitor (Omron M6
218 Comfort, Omron Healthcare, Kyoto, Japan). We averaged two readings, unless there was a
219 discrepancy of at least 10 mmHg in SBP or 5 mmHg in DBP, in which case we averaged three
220 readings. We also measured the weight and height of each participant.

221 For the imaging session, we selected, randomly if both eyes fulfilled the inclusion
222 criteria, one eye per participant. We performed macular and optic nerve head (ONH) structural
223 OCT imaging, as well as parafoveal OCT-A (Canon HS100 SD-OCT, Tokyo, Japan). The device
224 automatically segments and quantifies macular RNFL (mRNFL) thickness and ganglion cell-

225 inner plexiform layer (GCIPL) within a 10-mm diameter circular region of interest (ROI) centered
226 at the fovea (Figure 1A), a region which has been shown to be advantageous over the
227 commonly used 5-mm diameter ROI for mRNFL measurements.³⁷ It also reports peripapillary
228 RNFL (pRNFL) thickness at a 3.45-mm diameter circle centered at the ONH (Figure 1B). We
229 further subdivided pRNFL into temporal, superior, nasal, and inferior. We additionally acquired
230 two 6x6 mm OCT-A scans centered at the fovea (Figure 1C). We required an image quality of
231 7/10 or better, as well as the absence of any artifacts or segmentation errors for all OCT and
232 OCT-A scans, resulting in the exclusion of 9 out of the 105 subjects.

233 After registering and binarizing the signal of the en face OCT-A images, we calculated
234 the fractal dimension (FD) of the superficial vascular plexus, inside a 3-mm diameter circle
235 centered at the fovea (Figure 1C). We have previously provided details on FD and its
236 calculation, as well as on the specifications and repeatability of the Canon OCT-A.^{28,38} In short,
237 FD represents the complexity of the branching pattern and is lower in conditions with sparser
238 vasculature, such as glaucoma.³⁹

239 Lastly, we acquired two 45° high-quality and artifact-free fundus images (TRC-NW400,
240 Topcon Corporation, Tokyo, Japan), centered at the ONH (Figure 1D). For each image, we
241 derived the central retinal artery and vein equivalents (CRAE, CRVE; i.e., diameters) using the
242 standardized Knudtson-Parr-Hubbard iteration, whose details and validation can be found
243 elsewhere.^{28,40} In short, we back-calculated vessel diameters using the 6 largest arteriolar and 6
244 largest venular branches, identified within a ring centered at the ONH (2 and 3 optic disc
245 diameters). We recorded the average CRAE and CRVE of two images.

246

247 *Retinal blood flow and lower autoregulation limit*

248

249 We calculated total retinal vascular resistance (RVR) using the measured FD, CRAE,
250 and CRVE of each participant, as well as population-based hematocrit values (Lifelines

251 Biobank), adjusted for age, sex, and blood pressure status. We have previously documented
252 the mathematics behind this Poiseuille-based model and its validation in vivo.^{28,41} Subsequently,
253 we computed total RBF, using RVR and retinal perfusion pressure (RPP), a more precise
254 estimation of OPP for the retinal circulation²⁸:

255

$$256 \quad \text{RBF} = \frac{\text{RPP}}{\text{RVR}} \quad (1)$$

257 where $\text{RPP} = (0.39 \cdot \text{MAP} + 10.1) - \text{IOP}$ mmHg and $\text{MAP} = \frac{1}{3}\text{SBP} + \frac{2}{3}\text{DBP}$ is the mean arterial
258 pressure.

259

260 We defined LARL as the lowest RPP value for which RBF can be maintained constant
261 (Figure 2). At this critical point, the vasculature has reached its maximal autoregulatory capacity
262 and any further pressure drop will not trigger compensatory vasodilation, resulting in flow
263 reduction. We have previously shown that LARL can be approximated as:

264

$$265 \quad \text{LARL} = \text{RBF} \cdot \text{RVR}_{\text{max}} \quad (2)$$

266 where RVR_{max} is an upper bound observed in a population.²⁸

267

268 In this study, we defined RVR_{max} as the 95th percentile of the RVR distribution. Due to the
269 possible occurrence of structural remodeling in retinal vessels belonging to subjects with AHT,
270 we separated the RVR distributions of the non-hypertensives (groups 1 and 2) and
271 hypertensives (groups 3 and 4).¹²

272 Lastly, for each participant, we defined the *autoregulatory reserve* (AR) as the difference
273 between measured RPP and predicted LARL (Figure 2).

274

275

276 *Statistical analysis*

277

278 For the first part of the analysis, to establish the existence of a U-shaped association (if
279 any), we univariably compared structural OCT metrics (mRNFL, GCIPL, and pRNFL) between
280 the four BP groups. For the second part of the analysis, to investigate whether any vascular
281 factors could possibly explain this association, we univariably compared RVR, RBF, and AR
282 between the groups. For the last part of the analysis, we performed mediation analysis to
283 examine whether the vascular metrics lie in the explanatory pathway of the relationship between
284 MAP and the structural OCT metrics that were significant in the first part of the analysis.

285 We described normally distributed variables with the mean and standard deviation (SD)
286 and variables with a skewed distribution with the median and interquartile range (IQR). We used
287 one-way ANOVA with post hoc tests for group mean comparisons, adjusting for potential
288 confounders. To account for multiple testing, we implemented the Tukey HSD correction. We
289 applied Levene's test to check for equality of variances. Whenever ANOVA assumptions were
290 not met, we used non-parametric tests, Welch's one-way ANOVA with the Games-Howell
291 correction, or quantile regression.

292 To determine a mediation effect, we used Baron and Kenny's mediation steps.⁴² In short,
293 a vascular factor M was considered a mediator of the effect of MAP (X) on structural OCT (Y), if
294 the following were true in linear regression analysis:

- 295 a) X was a significant predictor of Y ($Y \sim X$).
- 296 b) X was a significant predictor of M ($M \sim X$).
- 297 c) When M was added to the model ($Y \sim X + M$), M was a significant predictor of Y and the
298 significance of X as a predictor of Y was reduced.

299 We verified these findings by using the Sobel test for indirect effects. Mediation analysis was
300 performed separately for the low BP group together with the controls, the treated AHT group

301 together with the controls, and the untreated AHT group together with the controls. RBF, RVR,
302 and AR were examined as potential mediators.

303 All analyses were performed using R (version 3.3.3; R Foundation for Statistical
304 Computing, Vienna, Austria) and SPSS (version 26; IBM Corp., Armonk, NY). A *P* value of 0.05
305 or less was considered statistically significant.

306

307 Results

308

309 In total, 96 eyes of 96 subjects fulfilled all the criteria and were included in the analysis.
310 Table 1 displays the characteristics of the population, stratified by BP status. Sex and BMI were
311 significantly different between groups, aside from BP. As expected, the low BP group comprised
312 almost exclusively females, while higher BMI was present in the hypertensive groups.^{43,44} Other
313 factors that could affect the comparisons, such as age, IOP, spherical equivalent (SEQ), and
314 ONH area, were similar between groups.

315

316 **Table 1.** Characteristics of the study population.

| | Group 1 (Low BP) | Group 2 (Normal BP) | Group 3 (Treated AHT) | Group 4 (Untreated AHT) | <i>P</i> value |
|-----------------------------------|-----------------------------|--------------------------------|----------------------------------|------------------------------------|-----------------------|
| Group size (<i>N</i>) | 31 | 21 | 26 | 18 | |
| Age; years [mean (SD)] | 56.1 (4.4) | 55.9 (4.7) | 56.4 (4.8) | 57.2 (4.6) | 0.81 |
| Sex; % female | 93.5 | 47.6 | 42.3 | 44.4 | <0.001 |
| SBP; mmHg [mean (SD)] | 106 (9) | 126 (6) | 142 (18) | 159 (22) | <0.001 |
| DBP; mmHg [mean (SD)] | 66 (6) | 79 (6) | 86 (11) | 99 (8) | <0.001 |

| | | | | | |
|---|------------------------|------------------------|------------------------|------------------------|------------------|
| BMI; kg·m⁻² [median (IQR)] | 22.1 (21.2 to 24.3) | 23.3 (22.1 to 26.5) | 26.9 (24.7 to 29.8) | 27.3 (24.3 to 28.4) | <0.001 |
| Smoking; % ever | 22.6 | 38.1 | 30.8 | 38.9 | 0.57 |
| IOP; mmHg [mean (SD)] | 13.9 (3.0) | 13.2 (3.1) | 14.3 (3.0) | 14.6 (3.7) | 0.56 |
| SEQ; D [mean (SD)] | -0.10 (1.41) | +0.27 (1.67) | -0.23 (1.55) | -0.68 (1.69) | 0.31 |
| ONH area; mm² [median (IQR)] | 1.89 (1.69 to 2.24) | 1.96 (1.71 to 2.20) | 1.94 (1.72 to 2.31) | 2.00 (1.78 to 2.29) | 0.75 |
| BP, blood pressure; AHT, arterial hypertension; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; IOP, intraocular pressure; SEQ, spherical equivalent; ONH, optic nerve head. | | | | | |

317

318 *Structural metrics*

319

320 Table 2 and Figure 3 present the comparison of structural OCT metrics across the four
 321 BP groups. Adjusted post hoc comparisons revealed that, compared to the controls, GCIPL was
 322 significantly thinner in the low BP group ($P_{adj} = 0.013$), the treated AHT group ($P_{adj} = 0.007$), and
 323 the untreated AHT group ($P_{adj} = 0.007$). The mRNFL was also thinner, but this was only
 324 significant for the treated AHT group ($P_{adj} = 0.001$). Interestingly, mRNFL in treated
 325 hypertensives was even significantly thinner than in untreated hypertensives ($P_{adj} = 0.033$).
 326 Figure 3 shows the characteristic (inverse) U shape for the macular OCT metrics. There was no
 327 clear effect of BP group on the mean pRNFL. However, treated hypertensives had a thinner
 328 temporal pRNFL ($P_{adj} = 0.045$) than normotensives. Also, inferior pRNFL was borderline thinner
 329 in subjects with low BP ($P_{adj} = 0.083$) and clearly thinner in both treated and untreated
 330 hypertensives ($P_{adj} = 0.034$ and 0.033 , respectively). Sex and BMI did not confound any of the

331 associations (all P values $\gg 0.05$) and this was still true after the omission of any group from
 332 the analysis.

333

334 **Table 2.** Structural OCT metrics as a function of BP status.

| | Group 1 (Low BP) | Group 2 (Normal BP) | Group 3 (Treated AHT) | Group 4 (Untreated AHT) | P value |
|--|-----------------------------|--------------------------------|----------------------------------|------------------------------------|-----------------------------|
| GCIPL; μm [mean (SD)] | 53.6 (2.7) | 56.2 (3.0) | 53.4 (3.3) | 53.1 (2.5) | 0.002 |
| mRNFL; μm [mean (SD)] | 37.7 (3.3) | 39.8 (3.4) | 36.0 (2.8) | 38.7 (3.4) | 0.001 |
| Total pRNFL; μm [mean (SD)] | 99.4 (8.2) | 103.1 (10.1) | 96.9 (9.2) | 100.3 (8.8) | 0.14 |
| Temporal pRNFL; μm [mean (SD)] | 71.8 (10.5) | 74.0 (8.1) | 65.5 (9.5) | 72.6 (15.3) | 0.038 |
| Superior pRNFL; μm [mean (SD)] | 119.6 (14.7) | 124.1 (16.7) | 119.5 (13.5) | 126.1 (16.6) | 0.36 |
| Nasal pRNFL; μm [mean (SD)] | 82.2 (11.2) | 80.6 (14.1) | 81.4 (11.4) | 80.6 (14.0) | 0.96 |
| Inferior pRNFL; μm [mean (SD)] | 124.5 (12.9) | 134.0 (13.3) | 122.7 (14.3) | 121.5 (15.7) | 0.019 |
| OCT, optical coherence tomography; BP, blood pressure; AHT, arterial hypertension; GCIPL, ganglion cell-inner plexiform layer; SD, standard deviation; mRNFL, macular retinal nerve fiber layer; pRNFL, peripapillary retinal nerve fiber layer. | | | | | |

335

336 *Vascular metrics*

337

338 Figure 4 displays RBF, RVR, and AR as a function of BP status. There were differences
 339 in RBF between groups ($P = 0.034$), but after adjusting for multiple comparisons RBF was only

340 significantly lower in the low BP group when compared to the untreated AHT group ($P_{adj} =$
341 0.043). RVR was also different between groups ($P = 9.0 \cdot 10^{-9}$), with the additional presence of a
342 larger variance in the treated AHT group (Levene's test: $P = 0.002$). With regards to AR, the
343 unequal variances were also statistically significant (Levene's test: $P = 0.0002$), showing that,
344 unlike any other group, treated hypertensives could have either a large or a small AR. As can be
345 better seen in Figure 5 and Supplementary Table S1, the low BP group had a significantly
346 smaller AR than the control group, regardless of AR quantile compared. Conversely, the
347 untreated hypertensives had a significantly larger AR than the control group, regardless of
348 quantile compared. However, there was a mixed response in the treated AHT group: the AR
349 was significantly smaller than that of the controls for small quantiles, while it was similar or
350 larger for larger quantiles. In addition, correlation analysis within the treated AHT group revealed
351 that the smaller AR quantiles corresponded to the lowest MAP values (Pearson's $r = 0.45$, $P =$
352 0.020), i.e., to the most intensively controlled hypertensives. Again, sex and BMI did not
353 confound these associations.

354

355 *Mediation analysis*

356

357 Results from mediation analysis regarding the effect of BP status on GCIPL are
358 presented in Table 3. RBF was mediating the association of GCIPL with BP within the combined
359 low BP group and controls, while RVR was mediating the same association within the combined
360 untreated AHT group and controls. RVR and AR were both independently mediating the
361 association of GCIPL with BP within the combined treated AHT group and controls. In the
362 complete model (GCIPL~MAP+RVR+AR), which accounts for the covariance between RVR and
363 AR, the opposite, real effect of AR became visible, that is, small AR was associated with thinner
364 GCIPL (see Discussion section). We did not observe any vascular mediation for the effect of BP
365 status on RNFL metrics.

366

367 **Table 3.** Effect of BP status on GCIPL: mediation analysis.

| | Low BP + controls (Group 1 + Group 2) | | Controls + treated AHT (Group 2 + Group 3) | | Controls + untreated AHT (Group 2 + Group 4) | |
|-------------------------------|--|--------------|---|--------------|---|---------------|
| | Effect | P value | Effect | P value | Effect | P value |
| Mediation step 1: | | | | | | |
| GCIPL ~ MAP | $b_{MAP} = 0.09$ | 0.052 | $b_{MAP} = -0.10$ | 0.043 | $b_{MAP} = -0.07$ | 0.032 |
| Mediation step 2: | | | | | | |
| RBF ~ MAP | $b_{MAP} = 0.27$ | 0.020 | N/A | N/A | N/A | N/A |
| RVR ~ MAP | N/A | N/A | $b_{MAP} = 0.005$ | 0.008 | $b_{MAP} = 0.005$ | 0.0003 |
| AR ~ MAP | N/A | N/A | $b_{MAP} = 0.17$ | 0.015 | N/A | N/A |
| Mediation step 3: | | | | | | |
| GCIPL ~ MAP + RBF | $b_{MAP} = 0.05$ | 0.30 | N/A | N/A | N/A | N/A |
| | $b_{RBF} = 0.16$ | 0.003 | N/A | N/A | N/A | N/A |
| GCIPL ~ MAP + RVR | N/A | N/A | $b_{MAP} = -0.04$ | 0.42 | $b_{MAP} = -0.03$ | 0.51 |
| | N/A | N/A | $b_{RVR} = -11.87$ | 0.001 | $b_{RVR} = -10.23$ | 0.022 |
| GCIPL ~ MAP + AR | N/A | N/A | $b_{MAP} = -0.06$ | 0.21 | N/A | N/A |
| | N/A | N/A | $b_{AR} = -0.21$ | 0.042 | N/A | N/A |
| GCIPL ~ MAP + RVR + AR | N/A | N/A | $b_{MAP} = -0.04$ | 0.40 | N/A | N/A |
| | N/A | N/A | $b_{RVR} = -27.37$ | 0.001 | N/A | N/A |
| | N/A | N/A | $b_{AR} = 0.47$ | 0.032 | N/A | N/A |
| Sobel test | 0.059 | | RVR: 0.041 ; AR: 0.095 | | 0.031 | |

BP, blood pressure; GCIPL, ganglion cell-inner plexiform layer; AHT, arterial hypertension; MAP, mean arterial pressure; RBF, retinal blood flow; RVR, retinal vascular resistance; AR, autoregulatory reserve; N/A, not applicable.

368

369 **Discussion**

370

371 In this study, we reported three main findings. Firstly, there exists an inverse U-shaped
372 effect between blood pressure status and structural OCT metrics (GCIPL and RNFL), with both
373 low and high blood pressure being associated with thinning of the inner retinal layers. Secondly,
374 despite the existence of retinal blood flow autoregulation, only a small autoregulatory reserve is
375 present in individuals with low blood pressure, as well as in individuals with intensively treated
376 arterial hypertension. Lastly, this compromised capacity for retinal blood flow regulation explains
377 (mediates) the effect of blood pressure status on the GCIPL.

378

379 *Low blood pressure*

380

381 This is, to our knowledge, the first study to uncover an association between low BP and
382 thinning of the inner retina in ophthalmologically healthy subjects. This relationship and its
383 vascular mediation were more pronounced for the GCIPL, which has been shown to be the
384 main layer of early NTG manifestation.⁴⁵ In addition, the association was entirely mediated by
385 RBF (no effect of sex, BMI, or other confounders in our population).

386 Indeed, we have previously shown that LARL for subjects without AHT corresponds to a
387 realistic SBP/DBP of ~105/65 mmHg (or even higher if IOP is above average).²⁸ Since, in the
388 present study, the average BP reading for the low BP group was at 106/66 mmHg, our finding
389 that this group had a borderline lower RBF (Figure 4, Table 3) and a considerably smaller AR

390 (Figure 5, Table S1) than controls is in line with our estimations and the general concept of
391 autoregulation.

392 Population studies have failed to report this association between low BP and GCIPL
393 thickness, possibly due to the implementation of linear models, but an explanation due to
394 differences in genetic background cannot be excluded.^{33,34} However, nonlinear models were
395 used in studies with glaucoma as the outcome measure and, in line with our findings, there is
396 evidence for the existence of increased glaucoma risk with low, usually diastolic or nocturnal,
397 BP.^{13–16,18,46}

398
399 *Hypertension*

400
401 Despite a slightly higher RBF and a considerably higher AR (Figures 4 and 5), untreated
402 hypertensives had thinner GCIPL, which has also been shown to be the location of first
403 progression in glaucoma patients with AHT.⁴⁵ This was mediated by RVR (Table 3), i.e., the
404 negative effect of increased BP to the GCIPL is explained by increased vascular resistance (but
405 not by reduced blood flow - see below). Nevertheless, it was the treated AHT group that
406 exhibited the most pronounced thinning and this was present in the majority of structural OCT
407 metrics (GCIPL, mRNFL, temporal pRNFL, inferior pRNFL). For this group, GCIPL thinning was
408 independently mediated by RVR and AR (Figure 5, Table 3). In the univariable models, large
409 RVR and large AR were both associated with thinner GCIPL, due to substantial covariance.
410 After controlling for the confounding effect of RVR, small AR was associated with thinner
411 GCIPL. This suggests that, in treated AHT, a combination of increased resistance and being
412 close to the autoregulatory tipping point explain the negative effect to the GCIPL.

413 GCIPL thinning without a decrease in RBF seems counterintuitive. However, even when
414 total RBF is largely unaffected, increased RVR results in increased blood velocity (i.e., reduced
415 transit time), shunting of flow, and reduced capillary density.^{47,48} This could affect red blood cell

416 distribution and retinal oxygen extraction. Smaller AR was additionally present in intensively
417 treated subjects (Figure 4C, Figure 5, Table S1), which could mimic low BP and lead to
418 hypoperfusion of the RGCs. In this regard, our results reflect a possible effect of the combined
419 rightward shift of the autoregulation curve (due to atherosclerosis and arteriosclerosis) and the
420 variations of the measured RPP (Figure 2), due to BP fluctuations throughout the day. Lastly,
421 chronic AHT also results in endothelial dysfunction and, therefore, impaired autoregulation.⁴⁹

422 A number of previous studies have also shown an effect of AHT on GCIPL and RNFL
423 thickness.^{21,29–32} However, some population-based studies did not detect this relationship.^{33,34}
424 Again, study design and analysis methods seem to be the most likely explanations for this
425 discrepancy. In all, the existence of thinner GCIPL in both low BP and AHT creates the
426 characteristic inverse U-shaped association. Regarding glaucoma risk, the role of AHT is
427 controversial. Most evidence points towards at least some benefit of timely AHT treatment,
428 possibly due to the prevention of microvascular damage, in combination with a slight IOP
429 lowering.^{24,50} However, it has been suggested that aggressive treatment of AHT could
430 negatively affect glaucoma and our results also point towards this direction.²⁰ The confounding
431 contribution of individual antihypertensive medications, whether neuroprotective or detrimental,
432 remains inconclusive.^{21–25}

433 We would like to stress here that, since there are benefits to intensive BP control with
434 regards to cardiovascular disease, our results should not be considered as a case for milder
435 treatment of AHT in general.^{51,52} However, since a J or U-shaped effect is reported in both fields
436 when intensive treatment becomes too intensive, our results could be a starting point for
437 discussion with cardiologists in individual cases where, for example, glaucoma continues to
438 deteriorate despite adequate IOP control.⁵³

439

440 *'Chicken-egg' dilemma*

441

442 From a theoretical standpoint, there exists a point in the pre-disease time course when
443 the very first vascular deficits or the very first structural deficits manifest. A subsequent causal
444 cascade of events would then result in further mutually mediated vascular and structural
445 deterioration, sometimes leading to a glaucoma diagnosis. By definition, cross-sectional studies
446 regarding perfusion in glaucoma cases are well past this critical point and cannot enhance our
447 understanding of the process.

448 In this regard, our study's novelty lies in demonstrating that interdependent structural
449 and vascular deficits related to a long-debated cardiovascular risk factor (especially low BP) can
450 even be traced back to whom we perceive as ophthalmologically healthy subjects. These results
451 suggest that a subtle GON precursor remains rather elusive, albeit present early on. While this
452 observation adequately explains the claim that perfusion deficits are already present prior to
453 glaucoma, it does not fully resolve the 'chicken-egg' dilemma (we showed that vascular deficits
454 are present without glaucoma, but not necessarily without smaller structural deficits). However,
455 the existence of different mediators between MAP and GCIPL thickness with different BP status,
456 hints towards a preceding vascular component. For example, there is no parsimonious
457 explanation for an intensive antihypertensive treatment strategy following GCIPL thinning.

458

459 *Study strengths and limitations*

460

461 The main strength of this study was the strict selection process which allowed us to look
462 at the true extremes of BP. This reduces the noise that usually characterizes larger population
463 studies and results in indirect loss of power. In addition, our linearity-free assumptions and the
464 categorizing of BP (rather than considering it as a continuous variable) allowed us to
465 differentiate between BP status and uncover a U-shaped association that was previously
466 elusive. Lastly, to our knowledge, this study is the first to provide a rigorous explanation of the

467 differential effect of BP status on retinal structure, by directly linking it to total RBF and its
468 autoregulation.

469 Due to the cross-sectional nature of our study, absence of data on the first occurrence of
470 AHT is a limitation. However, our threshold of an at least 1-year old diagnosis, together with the
471 selection procedure using multiple previous visits from another database, ensured no newly-
472 diagnosed cases (almost all cases had been diagnosed before at least 3 years). Secondly,
473 RBF, RVR, and AR were not directly measured, but indirectly calculated by means of their
474 measured components and a previously validated model. Indeed, we have previously shown in
475 an independent validation dataset that these outcomes strongly correlate with in vivo blood flow
476 metrics, as well as with structural metrics.²⁸ Unfortunately, there is currently no gold standard
477 way to quantify these parameters, but Doppler OCT is a frequently-used, promising tool. Our
478 predictive approach has the advantage of using more reproducible imaging techniques and,
479 most importantly, taking into account autoregulation limits. Combining these two methods could,
480 therefore, further finetune estimations. It should be also noted that our approach provides
481 information on the effect of static RBF autoregulation, but it is possible that BP status also
482 results in impairment of the autoregulatory latency, i.e., dynamic autoregulation. As such, our
483 results might only be part of a bigger underlying effect. Lastly, our population was predominantly
484 Caucasian; it is to be determined if the results can be generalized to other ethnicities.

485
486 In conclusion, we uncovered thinning of the GCIPL and RNFL related to both tails of the
487 blood pressure distribution (inverse U-shaped effect) and to intensive treatment of AHT, in
488 ophthalmically healthy individuals. We found that GCIPL thinning was associated with reduced
489 autoregulatory capacity of retinal blood flow. This predisposition to glaucomatous damage could
490 explain the frequent epidemiological finding of increased glaucoma risk in certain population
491 subgroups, such as subjects with nocturnal blood pressure dipping or aggressively treated
492 hypertension. Longitudinal studies are needed to confirm this postulation.

493 **References**

494

- 495 1. Schuman JS, Hee MR, Puliafito CA, et al. Quantification of nerve fiber layer thickness in normal
496 and glaucomatous eyes using optical coherence tomography. *Arch Ophthalmol*. 1995;113(5):586-
497 596.
- 498 2. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a
499 randomised, multicentre, placebo-controlled trial. *Lancet*. 2015;385(9975):1295-1304.
- 500 3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma
501 progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2002;120(10):1268-
502 1279.
- 503 4. Drance SM. Some factors in the production of low tension glaucoma. *Br J Ophthalmol*.
504 1972;56(3):229-242.
- 505 5. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Prog Retin Eye*
506 *Res*. 2002;21(4):359-393.
- 507 6. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. *Science*.
508 1991;254(5035):1178-1181.
- 509 7. Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitude-decorrelation angiography with optical
510 coherence tomography. *Opt Express*. 2012;20(4):4710.
- 511 8. Wojtkowski M, Leitgeb R, Kowalczyk A, Bajraszewski T, Fercher AF. In vivo human retinal
512 imaging by Fourier domain optical coherence tomography. *J Biomed Opt*. 2002;7(3):457.
- 513 9. Yarmohammadi A, Zangwill LM, Diniz-Filho A, et al. Relationship between Optical Coherence
514 Tomography Angiography Vessel Density and Severity of Visual Field Loss in Glaucoma.
515 *Ophthalmology*. 2016;123(12):2498-2508.
- 516 10. Yoshioka T, Song Y, Kawai M, et al. Retinal blood flow reduction in normal-tension glaucoma
517 with single-hemifield damage by Doppler optical coherence tomography. *Br J Ophthalmol*.
518 2021;105(1):124-130.
- 519 11. Hwang JC, Konduru R, Zhang X, et al. Relationship among visual field, blood flow, and neural
520 structure measurements in glaucoma. *Invest Ophthalmol Vis Sci*. 2012;53(6):3020-3026.
- 521 12. Hayreh SS. Blood flow in the optic nerve head and factors that may influence it. *Prog Retin Eye*

- 522 Res. 2001;20(5):595-624.
- 523 13. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest
524 glaucoma trial. *Ophthalmology*. 2007;114(11):1965-1972.
- 525 14. Leske MC, Wu S-Y, Hennis A, Honkanen R, Nemesure B, BESs Study Group. Risk factors for
526 incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology*. 2008;115(1):85-93.
- 527 15. Zheng Y, Wong TY, Mitchell P, Friedman DS, He M, Aung T. Distribution of Ocular Perfusion
528 Pressure and Its Relationship with Open-Angle Glaucoma: The Singapore Malay Eye Study. *Invest*
529 *Ophthalmol Vis Sci*. 2010;51(7):3399.
- 530 16. Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R, Los Angeles Latino Eye Study Group.
531 Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study.
532 *Invest Ophthalmol Vis Sci*. 2010;51(6):2872-2877.
- 533 17. Ramdas WD, Wolfs RCW, Hofman A, de Jong PTVM, Vingerling JR, Jansonius NM. Ocular
534 perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study.
535 *Invest Ophthalmol Vis Sci*. 2011;52(9):6875-6881.
- 536 18. Bowe A, Grünig M, Schubert J, et al. Circadian Variation in Arterial Blood Pressure and
537 Glaucomatous Optic Neuropathy—A Systematic Review and Meta-Analysis. *American Journal of*
538 *Hypertension*. 2015;28(9):1077-1082.
- 539 19. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle
540 glaucoma: a meta-analysis. *Am J Ophthalmol*. 2014;158(3):615-627.e9.
- 541 20. Topouzis F, Wilson MR, Harris A, et al. Association of open-angle glaucoma with perfusion
542 pressure status in the Thessaloniki Eye Study. *Am J Ophthalmol*. 2013;155(5):843-851.
- 543 21. Chong RS, Chee M-L, Tham Y-C, et al. Association of Antihypertensive Medication with Retinal
544 Nerve Fiber Layer and Ganglion Cell-Inner Plexiform Layer Thickness. *Ophthalmology*.
545 2020;31:S0161-6420(20)30739-9. doi:10.1016/j.ophtha.2020.07.051
- 546 22. Müskens RPHM, de Voogd S, Wolfs RCW, et al. Systemic antihypertensive medication and
547 incident open-angle glaucoma. *Ophthalmology*. 2007;114(12):2221-2226.
- 548 23. Zheng W, Dryja TP, Wei Z, et al. Systemic Medication Associations with Presumed Advanced or
549 Uncontrolled Primary Open-Angle Glaucoma. *Ophthalmology*. 2018;125(7):984-993.
- 550 24. Horwitz A, Klemp M, Jeppesen J, Tsai JC, Torp-Pedersen C, Kolko M. Antihypertensive

- 551 Medication Postpones the Onset of Glaucoma: Evidence from a Nationwide Study. *Hypertension*.
552 2017;69(2):202-210.
- 553 25. Pappelis K, Loisel AR, Visser S, Jansonius NM. Association of Systemic Medication Exposure
554 with Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal
555 Glaucoma Study. *Invest Ophthalmol Vis Sci*. 2019;60(14):4548-4555.
- 556 26. Asefa NG, Neustaeter A, Jansonius NM, Snieder H. Autonomic Dysfunction and Blood Pressure
557 in Glaucoma Patients: The Lifelines Cohort Study. *Invest Ophthalmol Vis Sci*. 2020;61(11):25.
- 558 27. Riva CE, Grunwald JE, Petrig BL. Autoregulation of human retinal blood flow. An investigation
559 with laser Doppler velocimetry. *Invest Ophthalmol Vis Sci*. 1986;27(12):1706-1712.
- 560 28. Pappelis K, Choritz L, Jansonius N. Microcirculatory model predicts blood flow and
561 autoregulation range in the human retina: in vivo investigation with Laser Speckle Flowgraphy. *Am J*
562 *Physiol Heart Circ Physiol*. 2020;319(6):H1253-H1273. doi:10.1152/ajpheart.00404.2020
- 563 29. Lee SH, Lee WH, Lim HB, Jo YJ, Kim JY. THICKNESSES OF CENTRAL MACULAR, RETINAL
564 NERVE FIBER, AND GANGLION CELL INNER PLEXIFORM LAYERS IN PATIENTS WITH
565 HYPERTENSION. *Retina*. 2019;39(9):1810-1818.
- 566 30. Lim HB, Lee MW, Park JH, Kim K, Jo YJ, Kim JY. Changes in Ganglion Cell–Inner Plexiform
567 Layer Thickness and Retinal Microvasculature in Hypertension: An Optical Coherence Tomography
568 Angiography Study. *Am J Ophthalmol*. 2019;199:167-176.
- 569 31. Akay F, Gündoğan FC, Yolcu U, Toyran S, Tunç E, Uzun S. Retinal structural changes in
570 systemic arterial hypertension: an OCT study. *Eur J Ophthalmol*. 2016;26(5):436-441.
- 571 32. Sahin OZ, Sahin SB, Ayaz T, et al. The impact of hypertension on retinal nerve fiber layer
572 thickness and its association with carotid intima media thickness. *Blood Press*. 2015;24(3):178-184.
- 573 33. Tham Y-C, Chee ML, Dai W, et al. Profiles of Ganglion Cell–Inner Plexiform Layer Thickness in a
574 Multi-Ethnic Asian Population. *Ophthalmology*. 2020;127(8):1064-1076.
- 575 34. Koh VT, Tham Y-C, Cheung CY, et al. Determinants of Ganglion Cell–Inner Plexiform Layer
576 Thickness Measured by High-Definition Optical Coherence Tomography. *Invest Ophthalmol Vis Sci*.
577 2012;53(9):5853.
- 578 35. Ende MY van der, van der Ende MY, Hartman MHT, et al. The LifeLines Cohort Study:
579 Prevalence and treatment of cardiovascular disease and risk factors. *Int J Cardiol*. 2017;228:495-
580 500.

- 581 36. Luft N, Wozniak PA, Aschinger GC, et al. Measurements of Retinal Perfusion Using Laser
582 Speckle Flowgraphy and Doppler Optical Coherence Tomography. *Invest Ophthalmol Vis Sci*.
583 2016;57(13):5417-5425.
- 584 37. Heikka T, Cense B, Jansonius NM. Retinal layer thicknesses retrieved with different
585 segmentation algorithms from optical coherence tomography scans acquired under different signal-
586 to-noise ratio conditions. *Biomed Opt Express*. 2020;11(12):7079.
- 587 38. Pappelis K, Jansonius NM. Quantification and Repeatability of Vessel Density and Flux as
588 Assessed by Optical Coherence Tomography Angiography. *Transl Vis Sci Technol*. 2019;8(3):3.
- 589 39. Al-Nosairy KO, Prabhakaran GT, Pappelis K, Thieme H, Hoffmann MB. Combined Multi-Modal
590 Assessment of Glaucomatous Damage with Electroretinography and Optical Coherence
591 Tomography/Angiography. *Transl Vis Sci Technol*. 2020;9(12):7.
- 592 40. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BEK. Revised formulas for
593 summarizing retinal vessel diameters. *Curr Eye Res*. 2003;27(3):143-149.
- 594 41. Takahashi T, Nagaoka T, Yanagida H, et al. A mathematical model for the distribution of
595 hemodynamic parameters in the human retinal microvascular network. *J Biorheol*. 2009;23(2):77-86.
- 596 42. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological
597 research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol*. 1986;51(6):1173-
598 1182.
- 599 43. Tigchelaar EF, Zhernakova A, Dekens JAM, et al. Cohort profile: LifeLines DEEP, a prospective,
600 general population cohort study in the northern Netherlands: study design and baseline
601 characteristics. *BMJ Open*. 2015;5(8):e006772.
- 602 44. Slagter SN, van Waateringe RP, van Beek AP, van der Klauw MM, Wolffenbuttel BHR, van
603 Vliet-Ostaptchouk JV. Sex, BMI and age differences in metabolic syndrome: the Dutch Lifelines
604 Cohort Study. *Endocr Connect*. 2017;6(4):278.
- 605 45. Marshall HN, Andrew NH, Hassall M, et al. Macular Ganglion Cell–Inner Plexiform Layer Loss
606 Precedes Peripapillary Retinal Nerve Fiber Layer Loss in Glaucoma with Lower Intraocular
607 Pressure. *Ophthalmology*. 2019;126(8):1119-1130.
- 608 46. Melgarejo JD, Lee JH, Petitto M, et al. Glaucomatous Optic Neuropathy Associated with
609 Nocturnal Dip in Blood Pressure: Findings from the Maracaibo Aging Study. *Ophthalmology*.
610 2018;125(6):807-814.

- 611 47. Leskova W, Warar R, Harris NR. Altered Retinal Hemodynamics and Mean Circulation Time in
612 Spontaneously Hypertensive Rats. *Invest Ophthalmol Vis Sci.* 2020;61(10):12.
- 613 48. Chua J, Chin CWL, Hong J, et al. Impact of hypertension on retinal capillary microvasculature
614 using optical coherence tomographic angiography. *J Hypertens.* 2019;37(3):572-580.
- 615 49. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial
616 function of the retinal vasculature in hypertensive patients. *Stroke.* 2004;35(6):1289-1293.
- 617 50. Klein BEK, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure:
618 longitudinal perspective: the Beaver Dam Eye Study. *Br J Ophthalmol.* 2005;89(3):284-287.
- 619 51. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular
620 disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-967.
- 621 52. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *J Hypertens.*
622 2019;37(1):226.
- 623 53. Böhm M, Schumacher H, Teo KK, et al. Achieved diastolic blood pressure and pulse pressure at
624 target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients:
625 results from ONTARGET and TRANSCEND trials. *Eur Heart J.* 2018;39(33):3105-3114.
- 626
627

628 **Figure 1.**

629

630 Structural (A-B) and vascular (C-D) regions of interest. A) Macular retinal nerve fiber layer

631 (mRNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses measured within the

632 larger (10-mm diameter) circle centered at the fovea, excluding the innermost 1-mm diameter

633 circle and the nasal sector of the outer ring. B) Peripapillary RNFL (pRNFL) measured at a circle

634 of 3.45-mm diameter centered at the optic nerve head (ONH). C) Optical Coherence

635 Tomography-Angiography (OCT-A) scan of 6x6 mm centered at the fovea. Signal intensity

636 inside the innermost 3-mm diameter circle is binarized in flow (black) and non-flow (white). D)

637 45° fundus image centered at the ONH. The 6 largest arterioles and 6 largest venules between

638 rings of 2 and 3 optic disc diameters are marked in blue.

639

640 **Figure 2.**

641

642 Theoretical autoregulation curve (axes in arbitrary units). Retinal blood flow (RBF) is displayed

643 as a function of retinal perfusion pressure (RPP). Within the autoregulation range, blood flow is

644 maintained constant. The distance of the actual (measured) RPP from the lower autoregulation

645 limit (LARL) is the autoregulatory reserve (AR).

646

647 **Figure 3.**

648

649 Ganglion cell-inner plexiform layer (GCIPL), macular retinal nerve fiber layer (mRNFL), and

650 peripapillary retinal nerve fiber layer (pRNFL) as a function of blood pressure (BP) status.

651 Significant differences after post hoc comparisons (adjusted for multiple testing) are marked.

652 The thicker layers observed in the control group (normal BP) than in the low BP or arterial

653 hypertension (AHT) groups create a characteristic (inverse) U shape.

654

655 **Figure 4.**

656

657 Absolute total retinal blood flow (RBF), retinal vascular resistance (RVR), and autoregulatory
658 reserve (AR) as a function of blood pressure (BP) status. Significant differences after post hoc
659 comparisons (adjusted for multiple testing) are marked. With increasing BP, RBF increases less
660 than RVR, resulting in an autoregulation effect visible in the first panel. A statistically significant
661 larger variability is observed for the AR of treated hypertensives (third panel), suggesting that
662 subjects in this group can be very close or very far from the lower autoregulation limit.

663

664 **Figure 5.**

665

666 Quantile regression models for autoregulatory reserve (AR) at each blood pressure (BP) status.
667 Parameter estimates (y-axis) represent the relative AR (compared to controls) for every AR
668 decile (x-axis). Low BP individuals (left panel) have a smaller AR than controls ($y < 0$), while
669 individuals with untreated arterial hypertension (AHT; right panel) have a larger AR than controls
670 ($y > 0$). Individuals with treated AHT (middle panel) have a smaller AR only when intensively
671 treated (leftmost deciles).

672

673

674

675

676


677

678

679

680 **Figure 1**


681



682


683

684 **Figure 2**



685


686 **Figure 3**
687



688

689 **Figure 4**


690



691

692 **Figure 5**

693



694